---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-016726"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2024-01-26T23:59:59+00:00"
generated_at: "2026-06-06T16:36:11.447136+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Homology Medicines furnishes Q32 Bio investor presentation for proposed merger; cash runway into mid-2026

## Summary
- Presentation highlights Q32's pipeline: bempikibart (phase 2 for alopecia areata/atopic dermatitis) and ADX-097 (phase 1/2 for complement-mediated diseases).
- Combined company expects cash, cash equivalents and short-term investments to fund operations into mid-2026.
- Merger expected to close in Q1 2024, subject to Homology stockholder approval and other customary conditions.
- CVRs may provide contingent payments to Q32 stockholders based on future milestones.

## SEC filing metadata
- accession: 0001193125-24-016726
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2024-01-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312524016726/0001193125-24-016726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312524016726/d736571d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-016726
- JSON: https://secwatch.observer/filing/0001193125-24-016726.json
- Plain text: https://secwatch.observer/filing/0001193125-24-016726.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.